Primary Total: $52,502,661
Total: $42,538,086
Primary Total: $39,077,134
Total: $32,087
Primary Total: $2,002
*A Phase I/II, Open-Label, Rising-Dose, Safety and Feasibility Study of SNX-111 Administered Intrathecally to Terminally Ill Patients Suffering from Chronic Pain, (428718), Neurex, $30,085 (adjustment).
*Equipping Medical Students to Manage Cancer Pain, (429735), National Hospice Fdtn, $2,000.
Comparison of Ultiva (TM) vs Fentanyl in Subjects Undergoing Coronary Artery Bypass Graft Surgery, (460101), Glaxo-Wellcome, $2.
For questions regarding listings, contact Ms. Deborah Davis, director of the Office of Sponsored Projects Administration, 214 Kinkead Hall, 0057, phone 257-8311. (ddavis@pop.uky.edu )
Last Updated: 6/30/03